Moberg Pharma AB (OSTO:MOB) Investments And Advances : kr0.00 Mil (As of Mar. 2025)

View and export this data going back to 2011. Start your Free Trial

What is Moberg Pharma AB Investments And Advances?

Moberg Pharma AB's Investments And Advances for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Moberg Pharma AB Investments And Advances Historical Data

The historical data trend for Moberg Pharma AB's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Moberg Pharma AB Investments And Advances Chart

Moberg Pharma AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec20

Dec21

Dec22

Dec23

Dec24

Investments And Advances

Get a 7-Day Free Trial

Moberg Pharma AB Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Moberg Pharma AB Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Moberg Pharma AB Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Moberg Pharma AB (OSTO:MOB) » Definitions » Investments And Advances

Traded in Other Exchanges

MBGPF:USA

Address

Gustavslundsvagen 42, 5th Floor, Bromma, Stockholm, SWE, SE-167 51

Website

https://www.mobergpharma.se

Moberg Pharma AB is a Swedish pharmaceutical company which develops and commercializes proprietary pharmaceuticals based on proven substances. The company develops and markets consumer healthcare products that relieve pain and treat skin conditions, mainly nail fungus. The Company's main product, MOB-015, is a novel topical treatment for onychomycosis It has a single operating segment, the development, and commercialization of medical products. Its geographic areas are Europe, the Americas, and Rest of the world.